34790-24-4

Usage

InChI:InChI=1/C9H8N2O/c1-6-7-4-2-3-5-8(7)11-9(12)10-6/h2-5H,1H3,(H,10,11,12)

Upstream product

• 685110-87-6 N-[2-[(trimethylsilanyl)ethynyl]phenyl]urea 
• 75-16-1 methylmagnesium bromide 
• 79-22-1 methyl chloroformate 
• 1885-29-6 anthranilic acid nitrile 
• 613-89-8 2-Aminoacetophenone 
• 551-93-9 2-aminoacetophenone 
• 69559-56-4 N-(2-acetylphenyl)-2,2,2-trichloroacetamide 

Downstream Products

• 1374568-14-5 C₂₀H₂₂N₄O 
• 1374568-46-3 C₂₀H₂₀N₄O₃ 
• 1374855-81-8 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-p-tolylacrylamide 
• 1374855-82-9 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethyl)phenyl)acrylamide 
• 1374855-83-0 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-methoxyphenyl)acrylamide 
• 1374855-84-1 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(difluoromethyl)phenyl)acrylamide 
• 1374855-85-2 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(difluoromethoxy)phenyl)acrylamide 
• 1374855-86-3 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(2,4-dichlorophenyl)acrylamide 
• 1374855-87-4 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(pyrrolidin-1-yl)phenyl)acrylamide 
• 1374855-88-5 (E)-3-(4-chlorophenyl)-N-(2-(4-hydroxy-4-phenylpiperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 
• 1374855-89-6 (E)-3-(4-chlorophenyl)-N-(2-(4-cyclobutyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 
• 1374855-90-9 (E)-3-(4-chlorophenyl)-N-(2-(4-hydroxy-4-isopropylpiperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 
• 1374855-91-0 (E)-3-(4-chlorophenyl)-N-(2-(4-hydroxy-4-propylpiperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 
• 1374855-92-1 (E)-3-(4-chlorophenyl)-N-(2-(4-ethyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 

Relevant academic research and scientific papers

N-Bu4NI-catalyzed selective dual amination of sp3 C-H bonds: Oxidative domino synthesis of imidazo[1,5-c]quinazolines on a gram-scale

An n-Bu4NI catalyzed domino reaction that involves selective dual amination of sp3 C-H bonds has been developed. The protocol affords a facile and efficient approach to the synthesis of imidazo[1,5-c] quinazolines under mild conditions.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2

Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in a sub-chronic DIO model with a good cardiovascular safety window.

NHC-stabilized gold(I) complexes: Suitable catalysts for 6-exo-dig heterocyclization of 1-(o-Ethynylaryl)ureas

Figure presented 3-substituted 1-(o-ethynylaryl)ureas 1 selectively undergo either 6-exo-dig or 5-endo-dig cyclization (to give 4-methylene-3,4-quinazolin- 2-ones 2 or indoles 3, respectively) depending on the choice of the metal, ligand, and reaction conditions. The best results (up to 96% yield) in the preparation of the hydroamination products 2 are achieved with the highly bulky NHC-stabilized cationic gold(I) complex [Au(IPr)]+. Conversely, ureas bearing an internal alkyne lead to the 5-endo-dig cyclization mode regardless of the gold(I) complex employed. Whereas the nature of the substituent at N-3 does not have any influence on the regiochemistry observed, it does, in some cases, affect the efficiency of these transformations.

An efficient synthesis of 4-alkyl-2(1H)-quinazolinones and 4-alkyl-2-chloroquinazolines from 1-(2-alkynylphenyl)ureas

An efficient synthesis of 4-alkyl-2(1H)-quinazolinones has been achieved by cyclization of 1-(2-alkynylphenyl)ureas (2 R2 = alkyl) in dichloroethane catalyzed by TfOH. In the case of aryl substitution (2 R2 = aryl), a mixture of quin

MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH

The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.

Quinazoline and benzimidazole MCH-1R antagonists

We have modified the previously reported 2-aminoquinoline 1 to provide two novel series of MCH-1R antagonists. Representative compounds from the quinazoline and benzimidazole series have been shown to be potent and selective, with promising in vitro eADME profiles.

BICYCLIC COMPOUNDS AND THEIR THERAPEUTIC USE

Compounds of the formula (1) are useful as MCH mediator, and in the therapy of obesity.

Antithrombotic quinoxazolines

Quinoxazolines having antithrombotic activity. Exemplary of those disclosed are: 4-{[6-(N-carboxymethyl-quinolin-8-yl-sulphonylamino)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, 4-{[6-(1-(N-cyclopentyl-carboxymethylcarbonylamino)-cyclo-propyl)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, and 4-{[7-(N-carboxymethylaminocarbonyl-ethylamino)-4-methyl-quinolin-2-yl]-oxo}-benzamidine.

Substituted pyrrolo [1,2-c] quinazolines and pharmaceutical compositions and methods employing them

Substituted pyrrolo[1,2-c] quinazolines useful for their cardiovascular activities and as antiasthmatic agents.